VBI Vaccines Inc. (VBIV) Stock Analysis

VBI Vaccines Inc. (VBIV) Healthcare & Pipeline Overview

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, leveraging its enveloped virus-like particle (eVLP) platform. The company's lead product, Sci-B-Vac, targets hepatitis B, while its pipeline includes vaccine candidates for glioblastoma, cytomegalovirus, and coronaviruses.

What Is the Investment Thesis for VBIV?

Key value drivers include the continued commercialization of Sci-B-Vac, the advancement of VBI-2601 (BRII-179) for chronic HBV infection, and the progress of its eVLP-based vaccine candidates, VBI-1901 for glioblastoma and VBI-1501 for cytomegalovirus. Growth catalysts include positive clinical trial results for its pipeline candidates, strategic partnerships, and potential regulatory approvals. However, the company's negative profit margin of -1069.3% and gross margin of -67.0% highlight significant financial risks. The company's high beta of 2.17 indicates high volatility relative to the market.

Based on FMP financials and quantitative analysis

VBIV Key Highlights

VBI Vaccines Inc. develops and sells vaccines for infectious diseases and immuno-oncology.

• Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine, is the company's lead commercial product.
• The company's eVLP platform is used to develop vaccine candidates for glioblastoma (VBI-1901) and cytomegalovirus (VBI-1501).
• VBI is developing VBI-2601 (BRII-179) as an immunotherapeutic candidate for chronic HBV infection.
• The company has collaboration agreements with Brii Biosciences Limited and GlaxoSmithKline Biologicals S.A.

Who Are VBIV's Competitors?

VBIV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VBIV's Key Strengths?

Proprietary eVLP platform technology.

• Commercialized hepatitis B vaccine (Sci-B-Vac).
• Strategic collaborations with Brii Biosciences and GlaxoSmithKline.
• Diverse pipeline of vaccine candidates targeting infectious diseases and immuno-oncology.

What Are VBIV's Weaknesses?

Negative profit margin and gross margin.

• Reliance on collaborations for development and commercialization.
• Limited financial resources compared to larger pharmaceutical companies.
• High beta indicates high volatility.

What Could Drive VBIV Stock Higher?

Clinical trial results for VBI-2601 (BRII-179) in chronic HBV infection.

• Clinical trial results for VBI-1901 in glioblastoma.
• Regulatory approvals for Sci-B-Vac in new markets.
• Progress in the development of coronavirus vaccine candidates.
• Expansion of collaborations with pharmaceutical and biotechnology companies.

What Are the Key Risks for VBIV?

Financial-distress signal — its Altman Z-Score of -14.88 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Regulatory setbacks and clinical trial failures.
• Competition from established pharmaceutical companies.
• Patent expiration and generic competition.
• Financial risks and need for additional funding.
• Dependence on collaborations for development and commercialization.

What Are the Growth Opportunities for VBIV?

• Advancement of VBI-2601 (BRII-179) for Chronic HBV Infection: VBI-2601, in collaboration with Brii Biosciences, targets the large market of chronic HBV infection. Positive clinical trial results and regulatory approvals could drive significant revenue growth. The ongoing collaboration with Brii Biosciences provides financial and developmental support for this program.
• Development of VBI-1901 for Glioblastoma: VBI-1901, a glioblastoma vaccine immunotherapeutic, addresses a critical unmet need in the treatment of this aggressive brain cancer. The glioblastoma market is expected to grow, driven by the aging population and advancements in cancer immunotherapy. Positive Phase I/IIa clinical study results could lead to further development and potential commercialization, creating a significant growth opportunity for VBI. This program leverages VBI's eVLP platform to stimulate an immune response against glioblastoma cells.
• Expansion of Sci-B-Vac Market Share: Sci-B-Vac, VBI's prophylactic hepatitis B vaccine, has the potential to expand its market share globally. Hepatitis B remains a significant public health concern, particularly in developing countries. By increasing production capacity, securing additional regulatory approvals, and expanding its distribution network, VBI can capitalize on the growing demand for HBV vaccines. This growth opportunity is supported by the established safety and efficacy profile of Sci-B-Vac.
• Development of Coronavirus Vaccine Candidates: VBI's coronavirus vaccine candidates, including VBI-2902 and VBI-2901, target COVID-19 and other coronaviruses. The ongoing COVID-19 pandemic and the potential for future coronavirus outbreaks create a significant market opportunity for effective vaccines. Collaborations with the National Research Council of Canada and CEPI enhance VBI's ability to develop and commercialize these vaccine candidates. Success in this area could generate substantial revenue and establish VBI as a key player in the coronavirus vaccine market.
• Licensing of Vaccine Platforms and Products: VBI's strategy includes licensing its vaccine platforms and products to pharmaceutical and biotechnology companies. This approach allows VBI to generate revenue through upfront payments, milestone payments, and royalties, while leveraging the resources and expertise of its partners. By actively seeking licensing agreements, VBI can diversify its revenue streams and accelerate the development and commercialization of its vaccine technologies. This strategy is particularly attractive for vaccine candidates targeting niche markets or requiring significant investment in manufacturing and distribution.

What Are VBIV's Competitive Advantages?

• Proprietary eVLP platform technology enables the development of novel vaccine candidates.
• Established commercial presence with Sci-B-Vac, a prophylactic hepatitis B vaccine.
• Strategic collaborations with Brii Biosciences Limited and GlaxoSmithKline Biologicals S.A.
• Intellectual property protection for its vaccine candidates and platform technologies.

What Does VBIV Do?

VBI Vaccines Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing vaccines for the treatment of infectious diseases and immuno-oncology. Founded with the mission of addressing unmet needs in global health through innovative vaccine technologies, VBI has evolved into a company with a diverse pipeline of vaccine candidates. The company's flagship product is Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. In addition to Sci-B-Vac, VBI is actively developing VBI-2601 (BRII-179), an immunotherapeutic candidate aimed at treating chronic HBV infection, in collaboration with Brii Biosciences. VBI's enveloped virus-like particle (eVLP) platform technology is central to its vaccine development efforts, enabling the creation of vaccines that mimic the natural presentation of viruses to the human immune system. This platform is being utilized to develop vaccine candidates such as VBI-1901, a glioblastoma vaccine immunotherapeutic currently in Phase I/IIa clinical study, and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. Furthermore, VBI is engaged in the development of coronavirus vaccine candidates, including VBI-2902 and VBI-2901, and collaborates with organizations like the National Research Council of Canada and the Coalition for Epidemic Preparedness Innovations (CEPI) to advance these efforts. Formerly known as SciVac Therapeutics Inc., the company rebranded as VBI Vaccines Inc. in May 2016 to reflect its broader focus on vaccine development across multiple therapeutic areas.

What Products and Services Does VBIV Offer?

• Develop and sell vaccines for infectious diseases.
• Develop and sell vaccines for immuno-oncology.
• Offer Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine.
• Develop VBI-2601 (BRII-179) for chronic HBV infection.
• Utilize the eVLP platform to develop vaccine candidates.
• Develop VBI-1901, a glioblastoma vaccine immunotherapeutic candidate.
• Develop VBI-1501, a prophylactic cytomegalovirus vaccine candidate.
• Develop coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.

How Does VBIV Make Money?

• Develop and commercialize vaccines for infectious diseases and immuno-oncology.
• Generate revenue through the sale of Sci-B-Vac and potential future vaccine products.
• Collaborate with pharmaceutical and biotechnology companies to develop and commercialize vaccine candidates.
• License vaccine platforms and products to generate revenue through upfront payments, milestone payments, and royalties.

What Industry Does VBIV Operate In?

VBI Vaccines Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant market potential. The global vaccine market is experiencing growth, driven by increasing awareness of preventative healthcare, rising incidence of infectious diseases, and advancements in vaccine technologies. VBI competes with established pharmaceutical companies and other biotechnology firms in the development and commercialization of vaccines. The company's eVLP platform provides a competitive advantage, enabling the development of novel vaccine candidates that mimic natural virus presentation.

Who Are VBIV's Key Customers?

• Individuals seeking protection against hepatitis B through vaccination.
• Patients with chronic HBV infection seeking immunotherapeutic treatment.
• Patients with glioblastoma seeking vaccine immunotherapeutic treatment.
• Individuals seeking protection against cytomegalovirus through vaccination.
• Pharmaceutical and biotechnology companies interested in licensing VBI's vaccine platforms and products.

Wall Street analysts project VBI Vaccines Inc. revenue of about $58.8M for fiscal 2026, with EPS near $-0.23.

VBIV Valuation & Market Position

With a $1.87M market cap, VBI Vaccines Inc. sits in the micro-cap segment of the market.

VBI Vaccines Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -14.88 places it in the distress zone, a signal of elevated financial risk.

VBI Vaccines Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.2% below estimates on average.

Company Profile

VBI Vaccines Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Jeffery R. Baxter FCMA. VBIV has traded publicly since 2010.

VBIV Financials

VBIV Latest News

What Investors Ask About VBI Vaccines Inc. (VBIV) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources